Canada markets closed

RepliCel Life Sciences Inc. (RP.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.05500.0000 (0.00%)
At close: 03:56PM EDT

RepliCel Life Sciences Inc.

570 Granville Street
Suite 900
Vancouver, BC V6C 3P1
604 248 8730

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Andrew SchuttePresident, CEO & Director8.92kN/A1990
Dr. Kevin John McElwee Ph.D.Co-Founder & Chief Scientific Officer30kN/A1970
Mr. Ben AustringChief Legal Officer, Corporate Secretary & COO14.5kN/AN/A
Dr. Rolf Hoffmann M.D.Chief Medical Officer & Member of Clinical Advisory BoardN/AN/A1962
Mr. David Kwok CPAChief Financial OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. The company was founded in 2006 and is headquartered in Vancouver, Canada.

Corporate Governance

RepliCel Life Sciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.